PURPOSE: To analyze the relationship between chromosomal instabilities and clinicopathological factors in synovial sarcoma (SS). METHODS: Twenty-two fresh-frozen SS were analyzed by metaphase comparative genomic hybridization (CGH). Additional microarray CGH was performed in 13 cases. RESULTS: Fourteen patients with SYT-SSX1 rearrangements and nine patients with biphasic tumor subtypes had better prognosis than the eight patients with SYT-SSX2 rearrangements and 13 patients with monophasic subtypes, respectively. Gains (average 3.0) were more frequent than losses (average 1.0). Frequent gains were identified on chromosomal regions 2, 6q, 7, 8q, 12, 17q, 18q, and 21q, whereas frequent losses were over-lapped on chromosomes 1p31-p35, 3p, 6q, 16, and 17p. High-level gains were observed on chromosomes 1q21-q31, 7, 8, 12, 17q, 18q, and 21q. Thirteen monophasic and nine biphasic tumors had an average of 5.1 and 2.8 aberrations, respectively. Patients with tumors harboring numerous aberrations (>or=3) had a worse clinical course. Microarray CGH more specifically detected genetic imbalances including gains in MDM2, MSH2, KCNK12, DCC, CDK2, ERBB3, SAS, and CDK4 and losses in HRAS, RASSF1, and CCND1. Gain of SAS was an important prognostic factor of SS. CONCLUSION: We have identified several factors influencing the prognosis of SS patients by metaphase and microarray CGH.
PURPOSE: To analyze the relationship between chromosomal instabilities and clinicopathological factors in synovial sarcoma (SS). METHODS: Twenty-two fresh-frozen SS were analyzed by metaphase comparative genomic hybridization (CGH). Additional microarray CGH was performed in 13 cases. RESULTS: Fourteen patients with SYT-SSX1 rearrangements and nine patients with biphasic tumor subtypes had better prognosis than the eight patients with SYT-SSX2 rearrangements and 13 patients with monophasic subtypes, respectively. Gains (average 3.0) were more frequent than losses (average 1.0). Frequent gains were identified on chromosomal regions 2, 6q, 7, 8q, 12, 17q, 18q, and 21q, whereas frequent losses were over-lapped on chromosomes 1p31-p35, 3p, 6q, 16, and 17p. High-level gains were observed on chromosomes 1q21-q31, 7, 8, 12, 17q, 18q, and 21q. Thirteen monophasic and nine biphasic tumors had an average of 5.1 and 2.8 aberrations, respectively. Patients with tumors harboring numerous aberrations (>or=3) had a worse clinical course. Microarray CGH more specifically detected genetic imbalances including gains in MDM2, MSH2, KCNK12, DCC, CDK2, ERBB3, SAS, and CDK4 and losses in HRAS, RASSF1, and CCND1. Gain of SAS was an important prognostic factor of SS. CONCLUSION: We have identified several factors influencing the prognosis of SS patients by metaphase and microarray CGH.
Authors: Marc Ladanyi; Cristina R Antonescu; Denis H Leung; James M Woodruff; Akira Kawai; John H Healey; Murray F Brennan; Julia A Bridge; James R Neff; Frederic G Barr; Jeffrey D Goldsmith; John S J Brooks; John R Goldblum; Syed Z Ali; Janet Shipley; Colin S Cooper; Cyril Fisher; Björn Skytting; Olle Larsson Journal: Cancer Res Date: 2002-01-01 Impact factor: 12.701
Authors: R Dammann; U Schagdarsurengin; C Seidel; M Strunnikova; M Rastetter; K Baier; G P Pfeifer Journal: Histol Histopathol Date: 2005-04 Impact factor: 2.303
Authors: D Sardon; I de la Fuente; E Calonge; M D Perez-Alenza; M Castaño; S Dunner; L Peña Journal: J Comp Pathol Date: 2005 Feb-Apr Impact factor: 1.311
Authors: F S Leach; T Tokino; P Meltzer; M Burrell; J D Oliner; S Smith; D E Hill; D Sidransky; K W Kinzler; B Vogelstein Journal: Cancer Res Date: 1993-05-15 Impact factor: 12.701
Authors: A J Crew; J Clark; C Fisher; S Gill; R Grimer; A Chand; J Shipley; B A Gusterson; C S Cooper Journal: EMBO J Date: 1995-05-15 Impact factor: 11.598
Authors: Nicholas McGranahan; Rebecca A Burrell; David Endesfelder; Marco R Novelli; Charles Swanton Journal: EMBO Rep Date: 2012-06-01 Impact factor: 8.807
Authors: Zsófia Balogh; Zsuzsanna Szemlaky; Miklós Szendroi; Imre Antal; Zsuzsanna Pápai; László Fónyad; Gergo Papp; Yi C Changchien; Zoltán Sápi Journal: Diagn Pathol Date: 2011-11-03 Impact factor: 2.644
Authors: Daniel Orbach; Véronique Mosseri; Daniel Pissaloux; Gaelle Pierron; Bernadette Brennan; Andrea Ferrari; Frederic Chibon; Gianni Bisogno; Gian Luca De Salvo; Camille Chakiba; Nadège Corradini; Véronique Minard-Colin; Anna Kelsey; Dominique Ranchère-Vince Journal: Cancer Med Date: 2018-03-13 Impact factor: 4.452
Authors: Johannes Tobias Thiel; Adrien Daigeler; Jonas Kolbenschlag; Katarzyna Rachunek; Sebastian Hoffmann Journal: Cancers (Basel) Date: 2022-07-12 Impact factor: 6.575
Authors: Myrella Vlenterie; Melissa H S Hillebrandt-Roeffen; Uta E Flucke; Patricia J T A Groenen; Bastiaan B J Tops; Eveline J Kamping; Rolph Pfundt; Diederik R H de Bruijn; Ad H M Geurts van Kessel; Han J H J M van Krieken; Winette T A van der Graaf; Yvonne M H Versleijen-Jonkers Journal: Oncotarget Date: 2015-10-27